Developing Precision Conjugates with Payload-driven ADC Design

Comprehensive systems-level approach designing first-in-class toxic payloads targeting and disrupting the cross-talk between the tumor and tumor microenvironment

Flipping the traditional ADC design approach on its head starting with novel precision payloads to maximize therapeutic potential of Elikya technology platform

Elikya’s next-gen ADCs leverage a unique class of toxic payloads

  • First-in-class payloads with differentiated mode of actions
  • Not subject to mechanisms of resistance
  • Strongly effective against tumors and key components of the TME
  • Potent and sustained memory response by stimulating the immune system

Adapted from Junttila and de Sauvage, Nature 2013.

Our Pipeline

Lead Candidates with Promising Preliminary Efficacy Results

ELY475
Solid Tumor
Concept
In Vivo POC
IND Enabling
Early Clinical
Late Clinical
ELY313
Solid Tumor
Concept
In Vivo POC
IND Enabling
Early Clinical
Late Clinical